Wall Street analysts expect that Mylan NV (NASDAQ:MYL) will announce $3.25 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Mylan’s earnings. The highest sales estimate is $3.28 billion and the lowest is $3.20 billion. Mylan reported sales of $3.08 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 5.5%. The firm is scheduled to report its next quarterly earnings report on Tuesday, February 25th.
On average, analysts expect that Mylan will report full-year sales of $11.56 billion for the current fiscal year, with estimates ranging from $11.50 billion to $11.59 billion. For the next financial year, analysts forecast that the business will post sales of $11.99 billion, with estimates ranging from $11.82 billion to $12.17 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Mylan.
Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.17 EPS for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.03. Mylan had a return on equity of 18.80% and a net margin of 0.42%. The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same quarter last year, the firm posted $1.25 earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year.
Shares of MYL stock traded up $0.87 during trading hours on Monday, reaching $19.68. The company had a trading volume of 6,148,623 shares, compared to its average volume of 6,015,542. Mylan has a 12 month low of $16.63 and a 12 month high of $32.23. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.43 and a quick ratio of 0.84. The business has a fifty day simple moving average of $18.37 and a 200-day simple moving average of $18.85. The company has a market cap of $9.71 billion, a price-to-earnings ratio of 4.30, a price-to-earnings-growth ratio of 1.02 and a beta of 1.71.
In other Mylan news, insider Goulds Bruce 8,000,000 shares of the company’s stock in a transaction dated Friday, November 8th. 0.81% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Mylan by 16.9% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 522,095 shares of the company’s stock valued at $14,796,000 after acquiring an additional 75,655 shares during the last quarter. Arizona State Retirement System raised its position in Mylan by 61.5% during the 2nd quarter. Arizona State Retirement System now owns 159,924 shares of the company’s stock valued at $3,045,000 after purchasing an additional 60,914 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its position in Mylan by 113.9% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 42,438 shares of the company’s stock valued at $808,000 after purchasing an additional 22,600 shares during the last quarter. Janney Montgomery Scott LLC raised its position in Mylan by 44.2% during the 2nd quarter. Janney Montgomery Scott LLC now owns 30,346 shares of the company’s stock valued at $578,000 after purchasing an additional 9,298 shares during the last quarter. Finally, Dupont Capital Management Corp raised its position in Mylan by 60.6% during the 2nd quarter. Dupont Capital Management Corp now owns 12,991 shares of the company’s stock valued at $247,000 after purchasing an additional 4,900 shares during the last quarter. Hedge funds and other institutional investors own 86.54% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.